HKE Holdings Limited Overview
HKE Holdings is a micro-cap hybrid that combines a profitable but small Singapore healthcare-construction niche with a loss-making Hong Kong financial-services venture. The core operating asset, Hwa Koon Engineering, is a specialist contractor for hospitals and clinics in Singapore. It has expertise in radiation-shielding works for diagnostic-imaging and radiotherapy rooms and delivers integrated design-and-build fit-outs plus maintenance. Since Mr. Lin Ho Man took control in 2021, the Group has spent heavily to build a Hong Kong virtual-asset platform. That platform is operated by Hong Kong BGE Limited, which received an SFC VATP licence on 17 June 2025, and it sits alongside an SFC-licensed advisory, asset-management and OTC-derivatives arm. Group losses have run at S$11–15 million a year since FY2022 and were funded through repeated equity placings. On 29 September 2026 management agreed to sell the FinTech Platform Business to entities linked to the controlling shareholder. That decision redirects the Group toward trading/asset management, healthcare and AI-related "asset-light" opportunities.
Company's own description (paraphrased from the FY2026 results announcement, MD&A)
The Group describes itself as a specialist contractor in the medical and healthcare sector with expertise in radiation-shielding works. It mainly provides integrated design and building services for hospitals and clinics in Singapore, which it calls the Engineering Business, and to a lesser extent maintenance and other services. From May 2021 it built a multi-asset FinTech service platform covering virtual assets, listed securities, listed bonds and alternative assets. Through two subsidiaries it also trades derivatives and provides advisory and asset-management services, which it calls the Trading and Asset Management Business. The stated aim of that arm was to diversify income and offer a full spectrum of financial services.
Operating segments (FY2026 definition)
-
Engineering Business. Integrated design and building services for healthcare facilities, including radiation shielding, M&E works and fitting-out, plus maintenance and other services and historically sales of tools and materials. Delivered in Singapore.
-
FinTech Platform Business. Virtual-asset trading platform services via Hong Kong BGE Limited. Its revenue was historically from virtual-asset custodian solutions via BGC Limited and BG Technologies Limited. This segment is to be disposed of under the agreements of 29 Sep 2026.
-
Trading and Asset Management Business. OTC derivatives trading (unlisted options and total return swaps), hedging services, asset management, and investment advisory/research support. It is run through Monmonkey Group Asset Management Limited (SFC Type 4 and Type 9) and Quality Union Limited.
-
Others. Investment holding and property investment, which sit below the reportable thresholds. Before FY2026 this was presented as an "Investment Holding" segment.
Revenue model and mix
| Revenue stream (SGD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Integrated design and building services (S$ M) | 9.620 | 12.116 | 16.131 | 20.485 | 17.740 |
| Maintenance and other services (S$ M) | 0.429 | 0.742 | 1.018 | 1.052 | 0.781 |
| Virtual assets custodian solutions (S$ M) | 0 | 0.585 | 0.313 | 0 | 0 |
| Asset management services (S$ M) | 0 | 0 | 0.314 | 0.574 | 0.933 |
| Investment advisory and research support (S$ M) | 0 | 0 | 0 | 0 | 0.131 |
| Hedging services income (S$ M) | 0 | 0 | 0 | 0.060 | 0.004 |
| Commission, handling and fee income (S$ M) | 0 | 0 | 0.018 | 0 | 0.002 |
| Net trading income, IFRS 9 (S$ M) | 0 | 0 | 0.639 | 0.807 | 0.087 |
| Total revenue (S$ M) | 10.048 | 13.443 | 18.433 | 22.977 | 19.679 |
Sources: FY2023, FY2024 and FY2026 results announcements, Note 5.
The model is project-based contracting with fixed-price contracts, which the filings say typically run one year or less. Revenue is recognised over time (S$18.8 million in FY2026) or at a point in time (S$0.8 million in FY2026). The Group has essentially no subscription or licensing revenue. The FinTech platform's fee revenue was negligible, at S$2,136 in FY2026. Financial-services revenue is a blend of fee income and trading P&L, and the trading P&L is volatile.
Value-chain position, customers and end-markets
In engineering, HKE operates as a specialist sub-contractor or turnkey contractor in hospital and clinic construction and refurbishment. It sits between medical-equipment vendors (CT, MRI, linear accelerators), main contractors and healthcare owners (public healthcare clusters and private hospital groups). Subcontractor costs were S$5.95 million in FY2026, which suggests an asset-light delivery model.
Customer concentration is extreme. In FY2026, four customers each exceeded 10% of revenue and together accounted for S$14.39 million, or about 73% (analyst-computed from FY2026 Note 5). Concentration was about 63% in FY2025, 48% in FY2024, 55% in FY2023 and 73% in FY2022.
Financial-services customers include institutional and professional clients. Material flows go through the connected brokerage Monmonkey Group Securities Limited (MMK), founded by the Chairman, which is the hedging-services counterparty and the planned anchor VATP client.
Independent characterisation
HKE is best understood as two businesses with opposite economics:
The engineering arm: is a small, cash-generative niche contractor. It turned in S$10–22 million of revenue and positive segment results every year FY2022–FY2026, but its segment margin compressed sharply from 22% in FY2022 to 0.4% in FY2026.
The FinTech arm: burned S$9–12 million a year in segment losses from FY2022 to FY2026, about S$55 million cumulatively (analyst-computed), and produced trivial revenue. In FY2026 its operating costs were about 45% of group administrative expenses, per the MD&A.
The Group's equity story since 2021 has rested on the FinTech option value, and the September 2026 decision to exit it marks a strategic reversal.
Strategy
Stated strategy (themes paraphrased from the FY2026 results announcement)
-
Exit the capital-intensive FinTech platform. Management concluded that structural crypto-market volatility and tighter licensing standards cloud the platform's growth outlook. FinTech costs were about 45% of group administrative expenses with no meaningful revenue since licensing, so management decided to dispose of it to protect group finances and shareholders' long-term interests.
-
Redeploy freed capital and management attention mainly into the Trading and Asset Management segment.
-
Diversify into sustainable-growth areas. The Group is evaluating projects in AI-related fields, healthcare and other efficient asset-light applications, with a stated balance between expansion and risk control.
-
Defend and grow the Singapore healthcare-construction niche. The thesis rests on Singapore's ageing population and the Ministry of Health facility pipeline, the Group's involvement in planning a new eastern hospital, entry into MRI-room shielding, and equipment replacement and pandemic-readiness upgrades.
Strategic initiatives in the last 24 months (Oct 2024–Oct 2026)
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Convertible bond financing | Jan–Feb 2025 | HK$26 million zero-coupon CB; 80% of proceeds to FinTech, 20% to working capital | Fully utilised by 30 Jun 2026 |
| BGE VATP licensing | 17 Jun 2025 | SFC Type 1, Type 7 and AMLO VATP licences | Achieved; platform launched Jan 2026 |
| Shareholder loan facility | Jun 2025 | About US$10 million from Lin Ho Man at 2.5%; US$8.5 million outstanding at 30 Jun 2026 | Due 15 May 2027 (extendable one year) |
| 2026 placing | Feb 2026 | 64 million shares at HK$1.20; net HK$76.0 million split 55% FinTech, 35% strategic equity investment, 10% working capital | HK$32.8 million of FinTech funds deployed; HK$26.6 million for strategic investment unutilised at 30 Jun 2026 (expected by 31 Dec 2026) |
| BG Ventures strategic investment | Feb 2026 agreement; Aug 2026 completion | About RMB60 million for 2.29% of an unnamed investee, via a partly-owned subsidiary with outside NCI capital | Completed |
| MMK VA cooperation framework | 29 May 2026 circular; 22 Jun 2026 EGM | BGE to provide platform and OTC services to MMK, with Quality Union as sole OTC liquidity provider through 30 Jun 2029; caps assume 100% annual VA volume growth from about US$313 million | EGM held; poll results published 22 Jun 2026. Now likely superseded by the disposal |
| FinTech disposal | 29 Sep 2026 | Sale of True Victor (HK$250.3 million total consideration including assignment of a HK$145.4 million shareholder loan) and Wonder Time (HK$0.5 million including a HK$189.5 million loan) to Finfra Holdings and Nexafin Investment, both connected to Lin | Pending independent shareholder approval; circular due by 31 Oct 2026 |
| Cost programme | FY2026 | Administrative expenses cut 9.8% (S$2.3 million); headcount −10 | Delivered; no forward numeric target disclosed |
| ESG | Annual | ESG report included in annual reports | No quantified targets identified |
Medium-term financial targets and guidance
Not publicly disclosed. Management provides qualitative outlook only and no revenue, margin or profitability targets.
Products & Services
Engineering Business (Hwa Koon Engineering Pte. Ltd., Singapore)
| Offering | Description | Target customer | Pricing model | Status / evidence |
|---|---|---|---|---|
| Radiation-shielding works | Design and construction of shielded rooms for X-ray, CT, nuclear medicine, linear accelerators and similar | Public hospitals, polyclinics, private hospitals, imaging centres | Fixed-price contracts, typically ≤1 year | Core competence per every MD&A FY2022–FY2026 |
| MRI room shielding (RF shielding) | New-market entry targeting MRI suites; management notes MRI waiting times of about 3 months | Hospitals adding diagnostic imaging capacity | Fixed-price | Stated as an intended market entry in the FY2026 MD&A; no revenue disclosed |
| Integrated design-and-build ("turnkey") | Combined design, radiation shielding, M&E and fitting-out for healthcare spaces | Healthcare owners and main contractors | Fixed-price, recognised over time | Largest revenue line: S$17.7 million in FY2026 |
| M&E works | Mechanical and electrical installation within healthcare fit-outs | As above | Within project price | Third-party profiles (Simply Wall St); bundled in integrated services |
| Fitting-out works | Interior fit-out of clinical spaces | As above | Within project price | Third-party profiles |
| Maintenance and other services | Post-completion maintenance and minor works | Existing facility owners | Point-in-time / service | S$0.78 million in FY2026 |
| Sales of tools and materials | Ancillary product sales | Contractors | Point-in-time | Disclosed in FY2024/FY2025 segment definitions; immaterial |
| New-hospital planning involvement | Participation in planning a new hospital in eastern Singapore | Public healthcare | — | FY2024 and FY2026 MD&A |
FinTech Platform Business (to be disposed)
| Offering | Entity | Description | Licence / launch | Pricing |
|---|---|---|---|---|
| BGE virtual-asset trading platform | Hong Kong BGE Limited | SFC-licensed spot VA exchange (order book) for selected virtual assets | SFC Type 1, Type 7 and AMLO VATP licences, 17 Jun 2025; official launch Jan 2026 | Trading fees; FY2026 fee income S$2,136 |
| BGE OTC trading desk | Hong Kong BGE Limited | Licensed OTC execution for large or customised VA trades, offered as a complement to the order book | Part of the VATP licence scope (HKEX, 16 Feb 2026) | Spread or fee; not disclosed |
| VA custody | BGE (as VATP) / formerly BGC Limited | Custody of client virtual assets and client money as required by VATP rules | BGC holds a TCSP licence (FY2023 MD&A) | — |
| Virtual-asset custodian solutions (wallet services) | BGC Limited, BG Technologies Limited | Wallet-service custody model | Launched FY2023; revenue S$0.585 million in FY2023 and S$0.313 million in FY2024, nil thereafter | Wallet service fees |
| Market data services and trading systems | Group FinTech subsidiaries | Market data, analytics, order-management and risk-management systems for equities | Market Data Vendor Licence approved by HKEx Information Services (FY2023 MD&A) | Not disclosed; no revenue reported |
| Planned VA services to MMK | BGE (platform/OTC) with Quality Union as sole OTC liquidity provider | Framework running 1 Jul 2026 to 30 Jun 2029, subject to approvals | EGM 22 Jun 2026 | Caps based on MMK's VA volume of about US$313 million (Mar 2025–Feb 2026) |
Trading and Asset Management Business
| Offering | Entity | Description | Licence | FY2026 revenue (SGD) |
|---|---|---|---|---|
| Asset management | Monmonkey Group Asset Management Limited | Management fees from managed funds | SFC Type 4 (advising on securities), Type 9 (asset management) | 932,698 |
| Investment advisory and research support | Monmonkey Group Asset Management | Advisory and research-support fees | Type 4 | 131,486 |
| Hedging services (OTC swaps) | Quality Union Limited | OTC swap trades with clients and related party MMK, under IFRS 15 | — | 4,437 |
| Proprietary and client-facing OTC derivatives | Quality Union Limited | Unlisted options and total return swaps; IFRS 9 net trading income | Not disclosed (SFC VA authorisation for QUL was pending in 2026) | 86,983 |
Others / Investment holding
Hong Kong investment properties: fair value S$4.04 million at 30 Jun 2026, down from S$5.25 million at 30 Jun 2022. Rental income was S$0.12 million in FY2026, and fair-value losses ran S$0.20–0.33 million a year in FY2024–FY2026.
BG Ventures Capital Limited: (partly owned): 2.29% stake in an unnamed independent investee for about RMB60 million (≈S$11.4 million), completed August 2026. Non-controlling interests rose to S$5.51 million at 30 Jun 2026.
Cryptocurrency holdings: S$0.82 million at 30 Jun 2026 (S$1.31 million a year earlier).
Financial Narrative
All figures are S$ millions for fiscal years ended 30 June. Sources: FY2023, FY2024 and FY2026 results announcements, which contain FY2022–FY2026 audited figures. Cash flow data for FY2022–FY2025 is from S&P Global Market Intelligence via StockAnalysis. The FY2026 cash flow statement is not yet available in the sources reviewed because the FY2026 annual report is pending.
Income statement
EBIT and EBITDA are analyst-computed: EBIT is pre-tax loss plus finance costs, and EBITDA is EBIT plus PPE and right-of-use depreciation.
Margins and growth (analyst-computed)
Revenue CAGR FY2022–FY2026: about 18.3% a year (analyst-computed: (19.679/10.048)^(1/4) − 1).
Commentary.
Revenue: Revenue nearly doubled from FY2022 to FY2025 on the post-COVID resumption of Singapore healthcare projects. The FY2023 MD&A notes projects returning to pre-pandemic levels, and the FY2025 commentary cites fewer but larger projects. FY2026 revenue fell 14.4% because customers undertook fewer construction projects (FY2026 MD&A).
Gross margin: Gross margin expanded from 30% to 46–48%. Management attributes this to higher-value, higher-margin projects from a more diversified customer base and to tighter cost control (FY2024 and FY2026 MD&A).
Cost structure: The cost base is the problem. Administrative expenses exceeded revenue every year and peaked at S$23.0 million in FY2025, driven by FinTech headcount, IT and licensing costs. The FY2026 cut of S$2.3 million (−9.8%) came alongside a fall in headcount from 113 to 103.
Finance costs: Finance costs more than doubled in FY2026 to S$0.37 million on interest on the US-dollar shareholder loan.
Inflection: The loss has stabilised in a S$12–14 million band but has never narrowed decisively. FY2026's attributable loss of S$12.2 million was the second-best of the five years.
Balance sheet
Debt composition: lease liabilities in every year, plus the HK$26 million convertible bond (fair value S$3.88 million in FY2025 and S$4.06 million in FY2026, current in FY2026) and the unsecured loan from Mr. Lin (S$12.62 million non-current in FY2025; S$11.15 million current in FY2026, due 15 May 2027 with a one-year extension option). No assets are pledged (FY2026 MD&A).
Commentary. The FY2024 balance-sheet spike to S$57.2 million was not an operating expansion. It reflected about S$23.4 million of client money in "amounts due to clients" and a matching receivable in the Trading and Asset Management business, which unwound in FY2025–FY2026.
Equity attributable to owners more than halved in FY2025 to S$13.0 million as losses outran a near-absence of new equity. In FY2026 it was partially rebuilt by the HK$76.8 million placing and the NCI capital injection into BG Ventures.
The Group switched from essentially debt-free to reliance on controlling-shareholder credit in June 2025. At 30 Jun 2026, S$15.2 million of the S$15.9 million total debt falls due within 12 months: the CB in February 2027 and the loan in May 2027. Against that, cash was S$27.6 million before the S$11.4 million BG Ventures commitment that settled in August 2026.
Cash flow
Columns run FY2022–FY2025 only, because FY2026 cash flow is not yet available in the sources reviewed.
Source: S&P Global Market Intelligence via StockAnalysis, last updated 30 Sep 2026.
The Company's own capex definition, which includes right-of-use additions and for FY2022 the property purchase, gives S$7.9 million in FY2022, S$0.4 million in FY2023, S$1.1 million in FY2024, S$0.9 million in FY2025 (PPE only) and S$0.3 million in FY2026 (PPE only), per the results announcements. FY2026 equity raised was about S$12.29 million net from the 26 Feb 2026 placing (FY2026 Note 17). No buybacks occurred in any year (results announcements).
Commentary. Free cash burn has been remarkably steady at S$10.5–15.0 million a year, about S$51.8 million cumulatively over FY2022–FY2025 (analyst-computed). It was funded by about S$36.1 million of equity over FY2022–FY2025, a further S$12.3 million in FY2026, and S$17.3 million of new debt in FY2025. The business has never been self-funding under current ownership.
Ratios (analyst-computed; year-end balances)
Non-meaningful ratios. These ratios are not meaningful in any year FY2022–FY2026 because EBITDA and EBIT were negative.
Commentary. Liquidity metrics weakened structurally. The current ratio fell from 6.0x in FY2023 to 1.5x in FY2026 as debt moved into current liabilities. Working-capital efficiency improved, with the cash conversion cycle down from about 99 days to 17–31 days, as supplier credit lengthened. That improvement is a modest positive inside an otherwise loss-dominated profile.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment revenue (SGD Mn)
| Segment revenue (SGD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Engineering Business (SGD Mn) | 10.048 | 12.858 | 17.149 | 21.537 | 18.522 |
FinTech Platform Business (SGD Mn) | 0 | 0.585 | 0.313 | 0 | 0.002 |
Trading and Asset Management (SGD Mn) | 0 | 0 | 0.971 | 1.441 | 1.156 |
Investment Holding / Others (SGD Mn) | 0 | 0 | 0 | 0 | 0 |
Total (SGD Mn) | 10.048 | 13.443 | 18.433 | 22.977 | 19.679 |
Revenue by Segment and Segment Assets & Liabilities
| Segment result (SGD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Engineering Business (SGD Mn) | 2.211 | 0.869 | 1.260 | 0.920 | 0.069 |
FinTech Platform Business (SGD Mn) | -10.342 | -12.301 | -11.281 | -11.783 | -9.193 |
Trading and Asset Management (SGD Mn) | 0 | 0 | -0.241 | 0.393 | 0.396 |
Investment Holding / Others (SGD Mn) | -3.012 | -3.365 | -2.809 | -3.468 | -3.795 |
Total segment results (SGD Mn) | -11.143 | -14.797 | -13.071 | -13.937 | -12.522 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Engineering segment margin (%) | 22.0 | 6.8 | 7.3 | 4.3 | 0.4 |
Engineering revenue YoY growth (%) | 0 | 28.0 | 33.4 | 25.6 | -14.0 |
Engineering share of group revenue (%) | 100.0 | 95.6 | 93.0 | 93.7 | 94.1 |
T&AM segment margin (%) | 0 | 0 | -24.8 | 27.3 | 34.3 |
T&AM share of group revenue (%) | 0 | 0 | 5.3 | 6.3 | 5.9 |
FinTech share of group revenue (%) | 0 | 4.4 | 1.7 | 0 | 0.01 |
Revenue by Segment and Segment Assets & Liabilities (Assets FY2025–Liabilities FY2026)
| Segment (SGD Mn) | Assets FY2025 | Assets FY2026 | Liabilities FY2025 | Liabilities FY2026 |
|---|---|---|---|---|
Engineering | 15.906 | 15.444 | 7.188 | 7.586 |
FinTech Platform | 14.271 | 16.163 | 1.282 | 0.919 |
Trading and Asset Management | 6.166 | 2.139 | 5.215 | 0.047 |
Others | 8.040 | 10.195 | 17.733 | 16.092 |
Total | 44.384 | 43.941 | 31.419 | 24.643 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (SGD Mn) | 10.048 | 13.443 | 18.433 | 22.977 | 19.679 |
Cost of services/sales (SGD Mn) | 7.019 | 8.960 | 9.596 | 13.807 | 10.575 |
Gross profit (SGD Mn) | 3.029 | 4.482 | 8.837 | 9.170 | 9.105 |
Other income (SGD Mn) | 0.257 | 0.504 | 0.569 | 0.413 | 0.422 |
Other gains/(losses), net (SGD Mn) | -0.062 | 0.019 | 0.626 | 0.036 | -0.542 |
Administrative expenses (SGD Mn) | 13.957 | 19.208 | 22.473 | 22.974 | 20.717 |
Operating income, EBIT before finance costs (SGD Mn) | -10.732 | -14.203 | -12.441 | -13.354 | -11.733 |
Depreciation, PPE + right-of-use (SGD Mn) | 0.867 | 0.946 | 1.018 | 1.247 | 1.250 |
EBITDA (SGD Mn) | -9.865 | -13.257 | -11.423 | -12.107 | -10.483 |
Finance costs (SGD Mn) | 0.153 | 0.090 | 0.061 | 0.169 | 0.368 |
Pre-tax loss (SGD Mn) | -10.885 | -14.293 | -12.502 | -13.524 | -12.101 |
Income tax (SGD Mn) | -0.382 | -0.242 | -0.147 | -0.104 | 0.038 |
Net loss (SGD Mn) | -11.267 | -14.535 | -12.649 | -13.628 | -12.063 |
Net loss attributable to owners (SGD Mn) | -11.267 | -14.533 | -12.648 | -13.627 | -12.191 |
EPS basic (S$ cents) | -1.25 | -1.47 | -1.20 | -1.27 | -1.11 |
EPS diluted (S$ cents) | -1.25 | -1.47 | -1.20 | -1.29 | -1.11 |
Dividends per share (S$ cents) | 0 | 0 | 0 | 0 | 0 |
Total staff costs (SGD Mn) | 12.2 | 16.9 | 20.6 | 20.7 | 17.8 |
Margin Analysis (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 30.1 | 33.3 | 47.9 | 39.9 | 46.3 |
Operating margin (%) | -106.8 | -105.7 | -67.5 | -58.1 | -59.6 |
EBITDA margin (%) | -98.2 | -98.6 | -62.0 | -52.7 | -53.3 |
Net margin, attributable (%) | -112.1 | -108.1 | -68.6 | -59.3 | -61.9 |
Admin expenses / revenue (%) | 138.9 | 142.9 | 121.9 | 100.0 | 105.3 |
Revenue YoY growth (%) | 0 | 33.8 | 37.1 | 24.6 | -14.4 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (SGD Mn) | 33.445 | 34.761 | 57.215 | 44.384 | 43.941 |
Cash and bank balances (SGD Mn) | 18.932 | 19.155 | 15.716 | 18.459 | 27.566 |
Trade receivables (SGD Mn) | 3.250 | 3.744 | 3.441 | 5.123 | 5.087 |
Contract assets (SGD Mn) | 2.522 | 3.645 | 4.402 | 5.422 | 3.045 |
Cryptocurrencies (SGD Mn) | 0.012 | 0.440 | 1.325 | 1.312 | 0.824 |
Investment properties (SGD Mn) | 5.249 | 5.112 | 4.942 | 4.293 | 4.039 |
Goodwill (SGD Mn) | 0 | 0 | 0.032 | 0.032 | 0.032 |
Short-term debt incl. current leases, CB, current loans (SGD Mn) | 0.891 | 0.527 | 0.394 | 4.570 | 15.819 |
Long-term debt incl. non-current leases and loans (SGD Mn) | 0.473 | 0.128 | 0.299 | 13.165 | 0.099 |
Total debt (SGD Mn) | 1.364 | 0.656 | 0.693 | 17.735 | 15.918 |
Net debt, negative = net cash (SGD Mn) | -17.568 | -18.499 | -15.023 | -0.724 | -11.648 |
Total liabilities (SGD Mn) | 5.003 | 4.706 | 30.387 | 31.419 | 24.643 |
Equity attributable to owners (SGD Mn) | 28.443 | 30.058 | 26.831 | 12.970 | 13.783 |
Non-controlling interests (SGD Mn) | -0.001 | -0.003 | -0.004 | -0.004 | 5.514 |
Total equity (SGD Mn) | 28.442 | 30.055 | 26.828 | 12.966 | 19.297 |
Working capital, net current assets (SGD Mn) | 20.756 | 22.905 | 19.893 | 18.656 | 12.959 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Operating cash flow (SGD Mn) | -9.48 | -14.84 | -12.12 | -12.61 |
Capital expenditure, PPE (SGD Mn) | -1.02 | -0.20 | -0.60 | -0.92 |
Free cash flow (SGD Mn) | -10.50 | -15.04 | -12.72 | -13.53 |
Purchase of real estate (SGD Mn) | -5.16 | 0 | 0 | 0 |
Equity issuance proceeds (SGD Mn) | 10.99 | 16.06 | 8.86 | 0.22 |
Net debt issued/(repaid) incl. leases (SGD Mn) | -0.37 | -0.74 | -0.66 | 16.60 |
Dividends paid (SGD Mn) | 0 | 0 | 0 | 0 |
Share buybacks (SGD Mn) | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE, attributable loss / year-end owners' equity (%) | -39.6 | -48.3 | -47.1 | -105.1 | -88.4 |
ROA, net loss / total assets (%) | -33.7 | -41.8 | -22.1 | -30.7 | -27.5 |
ROIC, EBIT / (equity + debt − cash) (%) | -98.7 | -122.9 | -105.4 | -109.1 | -153.4 |
Current ratio (x) | 5.6 | 6.0 | 1.7 | 2.0 | 1.5 |
Debt / equity, total debt / total equity (%) | 4.8 | 2.2 | 2.6 | 136.8 | 82.5 |
Gearing, company definition: interest-bearing liabilities / total assets (%) | 4.1 | 1.9 | 1.2 | 31.2 | 27.0 |
Asset turnover, revenue / total assets (x) | 0.30 | 0.39 | 0.32 | 0.52 | 0.45 |
DSO, trade receivables only (days) | 118.1 | 101.7 | 68.1 | 81.4 | 94.4 |
DPO, trade payables / cost of sales (days) | 19.5 | 23.8 | 49.5 | 64.8 | 63.4 |
Cash conversion cycle, no inventory (days) | 98.6 | 77.9 | 18.6 | 16.6 | 31.0 |
Financial Analysis
| Ratio | Assessment |
|---|---|
Net debt / EBITDA | Not meaningful. The Group was in net cash every year, with the minimum of S$0.7 million in FY2025 |
Interest coverage, EBIT / finance costs | Negative every year: about -70x in FY2022, -158x in FY2023, -203x in FY2024, -79x in FY2025 and -32x in FY2026 |
P/E | Not meaningful (loss-making) |
Region revenue (SGD Mn)
| Region revenue (SGD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Singapore (SGD Mn) | 10.048 | 12.858 | 17.149 | 21.537 | 18.522 |
Hong Kong and others (SGD Mn) | 0 | 0.585 | 1.284 | 1.441 | 1.158 |
Mainland China (SGD Mn) | 0 | 0 | 0 | 0 | 0 |
Total (SGD Mn) | 10.048 | 13.443 | 18.433 | 22.977 | 19.679 |
Geographic share and growth (%)
| Geographic share and growth (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Singapore share (%) | 100 | 96 | 93 | 94 | 94 |
Singapore YoY growth (%) | 0 | 28.0 | 33.4 | 25.6 | -14.0 |
Hong Kong and others YoY growth (%) | 0 | 0 | 119.6 | 12.2 | -19.6 |
Region non-current assets (SGD Mn)
| Region non-current assets (SGD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Hong Kong and others (SGD Mn) | 6.684 | 6.441 | 6.361 | 6.307 | 5.359 |
Mainland China (SGD Mn) | 0.712 | 0.243 | 0.252 | 0.269 | 0.112 |
Singapore (SGD Mn) | 0.593 | 0.621 | 0.656 | 0.641 | 0.696 |
Share Count (millions) and Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Shares in issue at FY end (millions) | 960.00 | 1,050.03 | 1,076.08 | 1,077.75 | 1,141.75 |
Weighted average shares, basic (millions) | 898.63 | 991.81 | 1,052.47 | 1,076.76 | 1,099.66 |
Equity raised, gross (HKD Mn) | 64.0 | 94.5 | 51.1 | 26.0 | 76.8 |
Placing / issue price (HKD) | 0.40 | 1.05 | 2.00 | 2.50 | 1.20 |
Share Price & Returns
| Reference point | Price (HKD) | Source |
|---|---|---|
2021 change-of-control offer price | 0.188 | HKEX, 21 May 2021 |
8 Jul 2025 | 1.53 | Stoxray |
≈8 Nov 2025 | ≈1.59 (derived from TipRanks market cap HK$1.71bn ÷ 1,077.7m shares) | TipRanks (derived) |
52-week range as of Nov 2025 | 1.20 – 2.37 | TipRanks |
30 Jul 2026 | 1.00 | Lixinger |
29 Sep 2026 | 0.74 | StockAnalysis |
30 Sep 2026 | 0.45 (−38.8%) | StockAnalysis |
2 Oct 2026 | 0.28 (−38.9%) | StockAnalysis |
5 Oct 2026 | 0.24 (−14.6%) | StockAnalysis |
9 Oct 2026 | 0.255 | StockAnalysis |
Valuation Multiples
| Multiple | HKE Holdings | Basis |
|---|---|---|
Market capitalisation | HK$291m / ≈S$47.5m | 1,141.75m shares; S$0.163/HK$ |
Enterprise value (excl. NCI) | ≈S$35.8m | Mcap + debt S$15.9m − cash S$27.6m |
EV/Sales (FY2026) | ≈1.8x | S$35.8m / S$19.7m |
P/Sales (FY2026) | ≈2.4x | S$47.5m / S$19.7m |
P/B (owners' equity S$13.8m) | ≈3.4x | — |
Capital Instruments
| Instrument | Amount | Rate | Maturity |
|---|---|---|---|
Unsecured loan from Lin Ho Man | S$11.15m (US$8.5m principal plus US$0.13m interest payable) | 2.5% p.a. | 15 May 2027 (one-year extension by mutual agreement) |
Zero-coupon convertible bond (FVTPL) | S$4.06m fair value (HK$26m principal) | 0% | 19 Feb 2027; convertible at HK$2.50, currently far out of the money |
Lease liabilities | S$0.70m | — | S$0.60m within 1 year |
Analyst Conclusions
Management guidance
Guidance is qualitative only. Management intends to complete the FinTech disposal, redirect resources to Trading and Asset Management, and evaluate AI, healthcare and asset-light projects. It remains positive on Singapore healthcare-construction demand, including MRI shielding entry and new-hospital planning (FY2026 MD&A). No quantitative guidance is published, and there are no consensus forecasts.
Bull case
-
The overhead cliff disappears. FinTech consumed about 45% of S$20.7m of administrative expenses (≈S$9.3m) and produced a S$9.2m segment loss in FY2026. Removing it could leave a residual group running near breakeven, with engineering contributing gross profit of about S$8–9m. That is analyst inference, and the "Others" overhead of S$3.8m remains.
-
The balance sheet is rebuilt by the disposal. The stated aggregate consideration of HK$250.8m (≈S$40.9m), if realised in cash, would be close to the entire current market capitalisation of about S$47.5m. It would also cover the S$15.2m of 2027 maturities about 2.7 times.
-
A structural healthcare backlog supports the core. Singapore's 2030 polyclinic and hospital programme, plus the imaging backlog, underpin multi-year demand for a specialist with 46% group gross margin.
Bear case
-
Related-party value transfer. The FinTech assets were funded by minority-diluting placings: 55% of February 2026 proceeds (HK$41.8m allocated) went to FinTech only seven months before the sale to the controller. The terms assign HK$334.9m of loans for HK$250.8m. The market's 68% four-day decline signals that investors see unfavourable terms or uncertain settlement.
-
The core business is shrinking and losing margin. Engineering revenue fell 14% in FY2026 and its segment margin collapsed to 0.4%. Customer concentration of about 73% leaves revenue hostage to a handful of tenders.
-
The strategy is vague and capital may be misallocated again. "AI-related" and "asset-light" ambitions come without targets after five years of FinTech losses (≈S$55m). A further S$11.4m was committed to an undisclosed 2.29% minority stake. Repeated equity issuance has been the funding model.
Key catalysts and monitorables (next 12 months)
-
The disposal circular (by 31 Oct 2026): valuation, independent financial adviser opinion, payment terms and expected gain or loss.
-
The independent shareholder vote on the disposal, and whether consideration is settled in cash or by offset against the shareholder loan.
-
The AGM on 26 Nov 2026 and any general mandate for further issuance.
-
The H1 FY2027 interim results (around February 2027): residual-group cost base, engineering order intake and margin.
-
The refinancing or repayment of the CB (19 Feb 2027) and the shareholder loan (15 May 2027).
-
Disclosure of the BG Ventures investee and use of the HK$26.6m strategic-investment proceeds earmarked by 31 Dec 2026.
-
Further board, executive or auditor changes, and public-float compliance.
Analyst verdict
HKE Holdings is at an inflection, but the direction is not yet clear. The underlying operating franchise is real but small: a niche Singapore healthcare contractor. That business generated S$18.5 million of revenue in FY2026, consistently positive segment results and group gross margins in the mid-40s. Since 2021, however, the investment case has been subordinated to a Hong Kong FinTech venture. That venture absorbed about S$55 million of segment losses, drove five rounds of dilution and turned a debt-free balance sheet into one reliant on controlling-shareholder credit. It produced an SFC-licensed exchange with almost no revenue.
The September 2026 decision to sell the platform to the Chairman's own vehicles is, in isolation, financially rational: it removes the single largest source of cash burn. But governance optics dominate the market's response. The Group bought its asset-management arm from a substantial-shareholder-linked vendor in 2023. In 2026 it raised minority capital earmarked for FinTech and then sold FinTech to the controller months later. It has cycled through three auditors since 2023. The share price fall from HK$0.74 to HK$0.255 erased about two-thirds of market value in days. At about S$36 million of EV (pre-BG Ventures settlement), the market now ascribes little value to either the disposal proceeds or the engineering business.
The equity therefore behaves as a binary option on the disposal's terms and settlement mechanics. If consideration is received substantially in cash and the residual group's overhead falls in line with FinTech's exit, the current valuation looks dislocated relative to stated proceeds and net cash. If instead proceeds are offset, deferred or eroded by fresh strategic ventures, persistent losses will continue to consume equity. Our stance is speculative and governance-discounted: the stock should be monitored and not underwritten until the circular confirms valuation, cash settlement and a credible cost plan for the residual group.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Background (from HKEX director announcements) |
|---|---|---|---|
Mr. Lin Ho Man (連浩民) | Chairman and Executive Director; controlling shareholder | Chairman/NED from 1 Jun 2021; ED from 19 Jan 2022 | Aged 28 at appointment in 2021, so about 33–34 now. Founder of Monmonkey Group Holdings. Community roles have included Tung Wah Group of Hospitals director (2021/22) and positions in Hong Kong youth and CPPCC-affiliated associations. |
Mr. Koh Lee Huat (許利發) | Executive Director | Since listing (2018); CEO at IPO | Long-standing Hwa Koon management; pre-IPO shareholder |
Mr. Cheng Yiu Mo (鄭耀武) | Non-executive Director | Since 19 Jan 2022 | — |
Mr. Lim Kai Jia Kesley (林凱佳) | Non-executive Director | Since 19 Jan 2022 | — |
Mr. Siu Man Ho Simon (蕭文豪) | INED | Since listing (2018) | Audit Committee member |
Prof. Pong Kam Keung (龐錦強) | INED | Since listing (2018) | Audit Committee member |
| — | INED; Audit Committee Chairman | — | — |
Ms. Lam Lam Nixie (林琳) | INED | Since 25 Apr 2025 | — |
Board & Management Changes
| Date | Change | Source |
|---|---|---|
25 Apr 2025 | Ms. Lam Lam Nixie appointed INED; a concurrent resignation recorded. Mr. Cheung Kwok Yan Wilfred, the former Audit Committee chair, no longer appears on the FY2026 board, so his departure around this date is inferred | Annual Report 2025 corporate information; FY2026 results |
23 Jul 2025 | Mr. Tsang Wing Fung resigned as Executive Director (ED since 2021) | Annual Report 2025; Interim Report 2026 |
1 Aug 2024 to 8 Jan 2026 | Mr. Zhou Peng appointed and then resigned as Executive Director | FY2024 results; Interim Report 2026 |
30 Jun 2026 | Company Secretary and Authorised Representative resigned and a replacement was appointed. The predecessor 何英傑 signed monthly returns to early 2026 | etnet announcement list; monthly returns |
Directors' Remuneration
| Metric (SGD Mn) | FY2025 | FY2026 |
|---|---|---|
Total directors' emoluments (SGD Mn) | 2.032 | 1.418 |
Share option expense, group (SGD Mn) | 0.084 | 0.075 |
Major Shareholders
| Holder | Shares | % of 1,141,746,668 | Source / note |
|---|---|---|---|
Flourish Nation Enterprises Ltd (Lin Ho Man) | 584,000,000 (last disclosed holding) | ≈51.2% (analyst-computed if unchanged) | Acquired Apr 2021 (73% of 800 million shares); 60.83% of 960 million shares per HKEX 19 Jan 2022. CCASS data shows about 568 million shares (49.72%) held through a single broker participant as of 19 Aug 2026, which may represent the controlling stake |
Mr. Lin Ho Man, share options | 800,000 options (as of Jan 2022) | — | HKEX, 19 Jan 2022 |
Public float (residual) | ≈48.8% if the controlling stake is unchanged | — | Analyst-computed |
Institutional holders, top 10 | Not publicly disclosed. No identifiable institutional holders were found; the register appears dominated by the controller and retail or brokerage nominees | — | CCASS snapshot (Lixinger) |
Competitive Landscape
Key Competitors
| Competitor / category | Relevance |
|---|---|
Specialist radiation-shielding contractors (Singapore SMEs) | Direct competitors in lead-lined rooms and bunkers |
Global RF/MRI shielding specialists (e.g., ETS-Lindgren) | Competitors in MRI-room shielding, the market HKE plans to enter |
Medical-equipment OEM turnkey programmes (imaging and radiotherapy vendors) | Can bundle room preparation with equipment supply |
General healthcare fit-out and M&E contractors in Singapore | Compete for design-and-build packages |
HKEX-listed small contractors (peer set used by data providers: Build King Holdings 240.HK, Able Engineering 1626.HK) | Valuation and size comparators, not direct competitors |
Competitor Detail
| Metric | HKE Holdings (FY2026) |
|---|---|
Revenue | S$19.7 million |
Revenue growth | −14.4% |
Gross margin | 46.3% |
Net margin | −61.9% |
R&D intensity | Not disclosed (FinTech loss/revenue 46.7%) |
Recent Developments
--



